Details
Stereochemistry | RACEMIC |
Molecular Formula | C28H38N4O6.2ClH |
Molecular Weight | 599.546 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.COC(=O)C1=C(C)NC(C)=C(C1C2=CC=CC(=C2)[N+]([O-])=O)C(=O)OCC(C)(C)CN3CCN(CC=C)CC3
InChI
InChIKey=PJGTYHKZUAHNHC-UHFFFAOYSA-N
InChI=1S/C28H38N4O6.2ClH/c1-7-11-30-12-14-31(15-13-30)17-28(4,5)18-38-27(34)24-20(3)29-19(2)23(26(33)37-6)25(24)21-9-8-10-22(16-21)32(35)36;;/h7-10,16,25,29H,1,11-15,17-18H2,2-6H3;2*1H
Molecular Formula | C28H38N4O6 |
Molecular Weight | 526.6245 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.chemdrug.com/article/8/3285/16420800.html
Sources: http://www.chemdrug.com/article/8/3285/16420800.html
Iganidipin is a new dihydropiridynic derivative of calcium antagonist. It is the only currently available calcium antagonist in the form of ophthalmic solution. Its topical administration increases ipsilateral optic nerve head blood flow in rabbits and monkeys and inhibits the contraction of blood vessels induced by endothelin -1. Iganidipin is also used for treat Angina pectoris and Hypertension.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363032 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7575741 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/12601046
for rabbit: (14)C-iganidipine solution (0.03%, 30 microL) was instilled into one eye
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16413513
Iganidipine (0.01-1 microM) increased the retinal ganglion cells (RGC) viability
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:12:36 GMT 2023
by
admin
on
Sat Dec 16 05:12:36 GMT 2023
|
Record UNII |
VEE2U6QF71
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
164031
Created by
admin on Sat Dec 16 05:12:37 GMT 2023 , Edited by admin on Sat Dec 16 05:12:37 GMT 2023
|
PRIMARY | |||
|
117241-46-0
Created by
admin on Sat Dec 16 05:12:37 GMT 2023 , Edited by admin on Sat Dec 16 05:12:37 GMT 2023
|
PRIMARY | |||
|
DTXSID40922373
Created by
admin on Sat Dec 16 05:12:37 GMT 2023 , Edited by admin on Sat Dec 16 05:12:37 GMT 2023
|
PRIMARY | |||
|
VEE2U6QF71
Created by
admin on Sat Dec 16 05:12:37 GMT 2023 , Edited by admin on Sat Dec 16 05:12:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |